Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436851 | 0.90 | MAPT (0.51) | MAPTLMNACYP3A4PGRAR | |
| Bolandiol Dipropionate SCHEMBL634970 | 0.86 | MAPT (0.57) | MAPTLMNACYP3A4PGRAR | |
| Bolandiol Dipropionate SCHEMBL30875871 | 0.86 | MAPT (0.57) | MAPTLMNACYP3A4PGRAR | |
| SCHEMBL5897156 | 0.80 | CYP3A4 (0.57) | MAPTLMNACYP3A4PGRAR | |
| SCHEMBL6441434 | 0.78 | MAPT (0.51) | MAPTLMNACYP3A4PGRAR | |
| SCHEMBL6446239 | 0.78 | MAPT (0.51) | MAPTLMNACYP3A4PGRAR | |
| SCHEMBL6436205 | 0.78 | MAPT (0.49) | MAPTLMNACYP3A4PGRAR | |
| SCHEMBL3463227 | 0.76 | LMNA (0.52) | MAPTLMNACYP3A4PGRAR | |
| SCHEMBL19303468 | 0.76 | LMNA (0.52) | MAPTLMNACYP3A4PGRAR | |
| SCHEMBL6446010 | 0.74 | CYP3A4 (0.56) | MAPTLMNACYP3A4PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134831-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | claimed |
| US-20050113354-A1 | Bioavailable prodrugs of androgenic steroids and related method | ROBERTS WILLIAM J (US) | 2005-05-26 | — | — | US | disclosed |
| US-6740646-B2 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2004-05-25 | — | — | US | disclosed |
| US-20030134830-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030134831-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | MAPT 4612/4885LMNA 436/4885CYP3A4 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.